Lorlatinib Outperforms Crizotinib in NSCLC.

The CROWN study suggests that lorlatinib is effective in patients newly diagnosed with advanced ALK-positive non-small cell lung cancer. In the phase III trial, patients treated with lorlatinib were twice as likely to be alive without disease progression after 1 year than those who received crizotinib-with slower progression of brain metastases. ©2020 American Association for Cancer Research.